Approval · Notice of Compliance 29264 · 2022
IBUPROFEN EXTRA STRENGTH CAPLETS: Notice of Compliance 29264
Issued October 21, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29264
- Date
- October 21, 2022
- Company
- Vita Health Products Inc.Winnipeg, Manitoba, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to package labels
- Canadian reference product
- ADVIL EXTRA STRENGTH CAPLETS (Glaxosmithkline Consumer Healthcare Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| IBUPROFEN EXTRA STRENGTH CAPLETS | Not yet assigned | — |
Medicinal ingredients
- IBUPROFEN 400 MG per TAB